Biota fundamentals

Use Biota Pharmaceuticals Inc (#AU000000BTA1AU) fundamentals together with your stock portfolios to protect against small markets fluctuations and to determine Stock optimization strategy that fits your criteria.  Suggest Portfolio

Biota competes with BHP BILLITON, ANGLOGLD, CWTH, RIO TINTO, and WESTPAC. It offers zanamivir, a neuraminidase inhibitor for the treatment and prophylaxis of influenza; and laninamivir for the treatment of influenza. Biota Holdings Ltd. also offer influenza diagnostics test kits, such as BioStar OIA FLU, which detects influenza and assists the physician to differentiate influenza from other respiratory infections that may display similar symptoms; and Biostar OIA FLU A/B, a flu test that distinguishes between influenza A and B. In addition, it discovers, develops, and commercializes antiinfective solutions for the treatment of influenza, respiratory syncytial virus, human rhinovirus, and hepatitis C; and new classes of antibiotics to treat hospitalacquired and communityassociated infections. Biota Holdings Ltd. has a coownership agreement with Daiichi Sankyo to manufacture and sell second generation inhaled antivirals in Japan; and a licensing agreement with GlaxoSmithKline to manufacture, market, and sell zanamivir worldwide. Biota Holdings Limited was incorporated in 1985 and is based in Notting Hill, Australia.